Ruud H Brakenhoff

List of Publications by Year
in descending order

88 papers	6,541 citations	172457 29 h-index	66911 78 g-index
90 all docs	90 docs citations	90 times ranked	8671 citing authors

#	Article	IF	Citations
1	The molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 9-22.	28.4	2,151
2	The molecular landscape of head and neck cancer. Nature Reviews Cancer, 2018, 18, 269-282.	28.4	897
3	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. International Journal of Cancer, 2007, 121, 2465-2472.	5.1	658
4	Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions. Head and Neck, 2002, 24, 198-206.	2.0	265
5	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. International Journal of Cancer, 2013, 132, 1565-1571.	5.1	177
6	Genetically Altered Fields as Origin of Locally Recurrent Head and Neck Cancer. Clinical Cancer Research, 2004, 10, 3607-3613.	7.0	163
7	Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients. Clinical Cancer Research, 2004, 10, 3614-3620.	7.0	152
8	Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study. British Journal of Radiology, 2018, 91, 20170498.	2.2	109
9	A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma. British Journal of Cancer, 2018, 119, 724-736.	6.4	95
10	Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. European Journal of Cancer, 2014, 50, 765-773.	2.8	79
11	Generation and Molecular Characterization of Head and Neck Squamous Cell Lines of Fanconi Anemia Patients. Cancer Research, 2005, 65, 1271-1276.	0.9	76
12	Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer. Clinical Cancer Research, 2013, 19, 1994-2003.	7.0	69
13	Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncology, 2011, 47, 956-960.	1.5	64
14	Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncology, 2013, 49, 560-566.	1.5	63
15	Molecular screening of oral precancer. Oral Oncology, 2013, 49, 1129-1135.	1.5	58
16	Minimal residual disease in head and neck cancer. , 1999, 18, 109-126.		51
17	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. Genomics, Proteomics and Bioinformatics, 2020, 18, 104-119.	6.9	51
18	ACE: absolute copy number estimation from low-coverage whole-genome sequencing data. Bioinformatics, 2019, 35, 2847-2849.	4.1	50

#	Article	IF	Citations
19	Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures. European Radiology, 2020, 30, 6311-6321.	4.5	49
20	Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. International Journal of Cancer, 2011, 128, 1852-1859.	5.1	48
21	Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. Oncogenesis, 2019, 8, 38.	4.9	48
22	Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. Nature Communications, 2015, 6, 8399.	12.8	46
23	Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer. Scientific Reports, 2020, 10, 4542.	3.3	46
24	Prevalence of human papillomavirus in laryngeal and hypopharyngeal squamous cell carcinomas in northern Spain. Cancer Epidemiology, 2015, 39, 37-41.	1.9	44
25	Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. , 1996, 68, 520-527.		35
26	The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma. International Journal of Cancer, 2021, 149, 420-430.	5.1	35
27	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. PLoS ONE, 2020, 15, e0232639.	2.5	35
28	DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells. PLoS ONE, 2013, 8, e61555.	2.5	34
29	Integration of highâ€risk human papillomavirus into cellular cancerâ€related genes in head and neck cancer cell lines. Head and Neck, 2017, 39, 840-852.	2.0	34
30	Characterization of cd44v6 isoforms in head-and-neck squamous-cell carcinoma. , 1999, 82, 837-845.		33
31	Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study. Oral Oncology, 2020, 110, 105014.	1.5	33
32	Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC. Molecular Cancer Therapeutics, 2015, 14, 1434-1444.	4.1	32
33	Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs secondary primary tumor. Oral Oncology, 2015, 51, 738-744.	1.5	31
34	Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer. Cancer Research, 2015, 75, 3543-3553.	0.9	30
35	Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. International Journal of Cancer, 2001, 92, 661-665.	5.1	28
36	Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC. Cancer Research, 2019, 79, 5597-5611.	0.9	28

#	Article	IF	Citations
37	Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients. Cancers, 2019, 11, 583.	3.7	28
38	Incorporation of differentiated dysplasia improves prediction of oral leukoplakia at increased risk of malignant progression. Modern Pathology, 2020, 33, 1033-1040.	5.5	28
39	Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients. Oral Oncology, 2020, 109, 104852.	1.5	27
40	Another NOTCH for Cancer. Science, 2011, 333, 1102-1103.	12.6	25
41	Establishment and Genetic Landscape of Precancer Cell Model Systems from the Head and Neck Mucosal Lining. Molecular Cancer Research, 2019, 17, 120-130.	3.4	25
42	The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics. Molecular Cancer Therapeutics, 2017, 16, 540-550.	4.1	24
43	Interaction of quantitative ^{18}Fâ€FDGâ€PETâ€CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head and Neck, 2016, 38, 529-535.	2.0	23
44	Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass. Oral Oncology, 2019, 98, 53-61.	1.5	22
45	Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget, 2017, 8, 59312-59323.	1.8	22
46	HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?. Oral Oncology, 2015, 51, 1057-1060.	1.5	21
47	Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation. Frontiers in Oncology, 2019, 9, 1470.	2.8	19
48	Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization. Cancers, 2021, 13, 2635.	3.7	19
49	Noninvasive Molecular Screening for Oral Precancer in Fanconi Anemia Patients. Cancer Prevention Research, 2015, 8, 1102-1111.	1.5	18
50	Molecular Patterns and Biology of HPV-Associated HNSCC. Recent Results in Cancer Research, 2017, 206, 37-56.	1.8	18
51	Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction. Journal of Proteomics, 2019, 196, 106-119.	2.4	18
52	Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy. Clinical Cancer Research, 2019, 25, 7256-7265.	7.0	18
53	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project. Head and Neck, 2021, 43, 601-612.	2.0	18
54	Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck. Oncotarget, 2017, 8, 97928-97940.	1.8	15

#	Article	IF	Citations
55	Generation of precursor cell lines from preneoplastic fields surrounding head and neck cancers. Head and Neck, 2013, 35, 568-574.	2.0	14
56	The course of health-related quality of life from diagnosis to two years follow-up in patients with oropharyngeal cancer: does HPV status matter?. Supportive Care in Cancer, 2021, 29, 4473-4483.	2.2	14
57	Unmet Needs and Perspectives in Oral Cancer Prevention. Cancers, 2022, 14, 1815.	3.7	14
58	Study retention and attrition in a longitudinal cohort study including patient-reported outcomes, fieldwork and biobank samples: results of the Netherlands quality of life and Biomedical cohort study (NET-QUBIC) among 739 head and neck cancer patients and 262 informal caregivers. BMC Medical Research Methodology, 2022, 22, 27.	3.1	13
59	Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. BMC Bioinformatics, 2018, 19, 301.	2.6	12
60	Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy. Radiotherapy and Oncology, 2020, 147, 186-194.	0.6	12
61	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. Cancers, 2021, 13, 3271.	3.7	12
62	Secreted protein markers in oral squamous cell carcinoma (OSCC). Clinical Proteomics, 2022, 19, 4.	2.1	12
63	Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art. Expert Review of Molecular Diagnostics, 2016, 16, 205-221.	3.1	11
64	Improved high-dimensional prediction with Random Forests by the use of co-data. BMC Bioinformatics, 2017, 18, 584.	2.6	11
65	Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. Cancers, 2021, 13, 2774.	3.7	11
66	Response to correspondence on the molecular biology of head and neck cancer. Nature Reviews Cancer, 2011, 11, 382-382.	28.4	10
67	BIOLOGIC IMPLICATIONS OF GENETIC CHANGES IN HEAD AND NECK SQUAMOUS CELL CARCINOGENESIS. ANZ Journal of Surgery, 1997, 67, 410-416.	0.7	9
68	Development and Validation of a Novel and Rapid Molecular Detection Method for High-Risk Human Papillomavirus in Formalin-Fixed, Paraffin-Embedded Tumor Tissue. Journal of Molecular Diagnostics, 2020, 22, 262-271.	2.8	8
69	Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition. Scientific Reports, 2020, 10, 2330.	3.3	8
70	Limited detection of human polyomaviruses in Fanconi anemia related squamous cell carcinoma. PLoS ONE, 2018, 13, e0209235.	2.5	7
71	Ovarian cancer–derived copy number alterations signatures are prognostic in chemoradiotherapy–treated head and neck squamous cell carcinoma. International Journal of Cancer, 2020, 147, 1732-1739.	5.1	6
72	Age-group-specific trend analyses of oropharyngeal squamous cell carcinoma incidence from 1989 to 2018 and risk factors profile by age-group in 2015–2018: a population-based study in The Netherlands. European Journal of Cancer Prevention, 2022, 31, 158-165.	1.3	6

#	Article	IF	Citations
73	Associations between clinical and histopathological characteristics in oral leukoplakia. Oral Diseases, 2023, 29, 696-706.	3.0	6
74	Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirusâ€"Positive Oropharyngeal Carcinoma. JCO Precision Oncology, 2021, 5, 1666-1676.	3.0	6
75	Genetic Classification of Oral and Oropharyngeal Carcinomas Identifies Subgroups with a Different Prognosis. Analytical Cellular Pathology, 2009, 31, 291-300.	1.4	5
76	Oral leukoplakia classification and staging system with incorporation of differentiated dysplasia. Oral Diseases, 2023, 29, 2667-2676.	3.0	5
77	At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. Frontiers in Oral Health, 2021, 2, 647980.	3.0	4
78	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. Oral Oncology, 2021, 121, 105454.	1.5	4
79	NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. International Journal of Molecular Sciences, 2021, 22, 11057.	4.1	4
80	Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. Oral Oncology, 2020, 109, 104851.	1.5	3
81	Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	2.8	2
82	Potentially novel options for treatment of HPV-attributable head and neck cancer. Cell Cycle, 2013, 12, 1020-1020.	2.6	0
83	Risk Groups for Survival in HPV-Positive and HPV-Negative OPSCC. Recent Results in Cancer Research, 2017, 206, 221-231.	1.8	0
84	889â€¦DuoBodyÂ®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo. , 2021, 9, A932-A932.		0
85	Title is missing!. , 2020, 15, e0232639.		0
86	Title is missing!. , 2020, 15, e0232639.		0
87	Title is missing!. , 2020, 15, e0232639.		0
88	Title is missing!. , 2020, 15, e0232639.		0